# NCT02628067 (NCT02628067)

> Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02628067
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Advanced Cancer; Anal Carcinoma; Anal Cancer; Biliary Cancer; Cholangiocarcinoma; Bile Duct Cancer; Neuroendocrine Tumor; Carcinoid Tumor; Endometrial Carcinoma; Endometrial Cancer; Cervical Carcinoma; Cervical Cancer; Vulvar Carcinoma; Vulvar Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer (SCLC); Mesothelioma; Thyroid Carcinoma; Thyroid Cancer; Salivary Gland Carcinoma; Salivary Gland Cancer; Salivary Cancer; Parotid Gland Cancer; Advanced Solid Tumors; Colorectal Carcinoma
- Interventions: pembrolizumab; pembrolizumab
- Enrollment: 1609
- Primary outcome: Objective Response Rate (ORR)

## Commentary we found

- Podcasts: 30
- YouTube: 25
- X threads: 24

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02628067

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02628067", "email": "<work email>"}; the inbox owner confirms by the emailed link.